Custom peptides are made almost universally by Fmoc solid-phase peptide synthesis: the chain is built on resin through iterative deprotection and coupling cycles, then cleaved and purified. The single most consequential input a researcher controls is the order specification itself. Get the sequence, scale, purity target, modifications, terminal groups, salt form, physical format and analytical package right, and the rest of the custom peptide synthesis process runs predictably. Sequence complexity, particularly length, hydrophobicity and multiple modifications, is what stretches lead time and drives cost.
The custom peptide synthesis process, step by step
Solid-phase peptide synthesis (SPPS) anchors the first (C-terminal) amino acid to an insoluble resin, then builds the chain one residue at a time. Each cycle removes the temporary protecting group from the growing chain's amino terminus, activates the next amino acid, couples it, washes away excess reagent, and caps any unreacted sites before moving on. Once the full sequence is assembled, the peptide is cleaved from the resin and the permanent side-chain protecting groups are stripped away, as detailed in reviews of automated SPPS.
Fmoc chemistry is the practical default for research-grade custom peptide orders because it is base-labile, orthogonal to the acid-stable side-chain protection, and compatible with automated synthesisers running standard building-block libraries. Advances in Fmoc-based SPPS show this orthogonality is what makes automation reliable at scale. Boc chemistry still has a place for certain specialist sequences and some cyclic or unusual backbone chemistries, but it demands harder acid deprotection conditions and is rarely the first choice for standard commercial peptide synthesis services.
The chemistry choices behind a given synthesis run typically include:
- Resin selection based on the desired C-terminal group (amide versus free acid) and target scale.
- Activating agents (such as HBTU, HATU or DIC/Oxyma combinations) chosen for coupling efficiency on a given sequence.
- Protecting-group strategy for side chains that must survive repeated deprotection cycles without side reactions.
- Capping steps that block unreacted amine sites, limiting deletion sequences that become difficult to separate later.
Cleavage, purification and fraction pooling explained
Once assembly finishes, the peptide is released from the resin using a cleavage cocktail, usually a strong acid mixture, alongside scavengers that trap reactive carbocations before they can alkylate sensitive side chains such as tryptophan or cysteine. This step also strips away the remaining permanent protecting groups, leaving a crude peptide mixture that still contains deletion sequences, truncated fragments and other by-products.
- Preparative reversed-phase HPLC separates the crude mixture by hydrophobicity, running against a purity specification agreed before synthesis begins.
- Fraction collection and assessment checks each fraction against the target purity and identity criteria, a practice documented in peptide purification reviews.
- Pooling combines fractions that meet the specification into a single main-pool batch, while borderline or side fractions are held aside.
- Repurification of those side fractions can recover additional usable material, though it adds processing time and typically yields peptide at a slightly lower net recovery than the main pool.
Explicit acceptance criteria for side fractions matter more than researchers often assume: without a declared limit, yield accounting and purity claims become ambiguous, a point the EMA's synthetic peptide guideline makes directly in the context of documented process controls.
What analytics prove a peptide is what you ordered
Identity and purity answer two different questions, and both need direct evidence rather than a supplier's assurance. Mass spectrometry, typically MALDI-TOF or ESI-MS, confirms the molecular mass matches the intended sequence. It does not tell you how much of the sample is that correct sequence versus truncated or deleted variants. That is what reversed-phase HPLC or UPLC integration reports, expressed as a percentage of the total peak area under defined run conditions.
Statistic in focus: synthesis quality problems rarely come from one cause. Incomplete coupling, side reactions during deprotection, and losses during purification each chip away at final purity, which is why factors affecting peptide purity recommends matching analytical depth to how sensitive your assay actually is to impurities.
Before placing a custom peptide order, request:
- Confirmed molecular identity by MS, with the raw spectrum available on request.
- An analytical HPLC/UPLC trace showing integration, not just a summary percentage.
- The declared salt form (TFA, acetate, HCl or free base) and any terminal modifications.
- A note on residual solvents or counterion content where the application is sensitive to it.
A Certificate of Analysis (COA) that bundles these elements is the minimum viable analytical package for laboratory research use. Anything less leaves a gap between what you ordered and what arrived.
Why sequence complexity changes yield and turnaround
Length, hydrophobicity, aggregation-prone motifs and stacked modifications all push against straightforward stepwise synthesis. Longer chains accumulate more chances for incomplete coupling at each cycle, and hydrophobic stretches tend to fold back on the resin, physically blocking reagent access. Practical SPPS protocols note that these difficult sequences often need special building blocks or restructured synthetic routes rather than a simple, unmodified run.
Common mitigation strategies include:
- Double coupling or extended reaction times at residues prone to poor incorporation.
- Pseudoproline dipeptide building blocks, which temporarily disrupt secondary structure formation on resin, as described in work on automated SPPS for therapeutic peptides.
- Reduced resin loading, giving each growing chain more physical space and lowering aggregation risk.
- Fragment condensation or ligation, assembling the target from two or more shorter, cleaner fragments.
Pro Tip: Ask any prospective provider what in-process monitoring they run, such as Kaiser, Chloranil or TNBS colour tests for free amine detection, and what their contingency plan is if a coupling step fails partway through. A provider who can answer specifically is managing the chemistry, not just running a program.
Choosing format, salt form and storage after synthesis
The counterion attached to your peptide, commonly trifluoroacetate (TFA), acetate, hydrochloride or free base, affects both mass and downstream assay behaviour, so it needs to be specified rather than assumed. Lyophilisation parameters, including freezing rate, primary drying temperature and residual moisture, materially influence how stable the final cake is in storage, a point research on peptide lyophilisation makes clear.
Practical handling guidance for delivered peptides:
- Confirm the salt form before running any concentration-sensitive assay.
- Store lyophilised peptide at the temperature the COA specifies, generally frozen and desiccated, until reconstitution.
- Reconstitute using solvent conditions matched to the peptide's solubility profile, not a generic default.
- Aliquot on receipt to avoid repeated freeze-thaw cycles degrading the working stock, following the same aseptic handling and COA-verified aliquotting practice labs use for sterility-sensitive samples.
Building a custom peptide quote request that gets an accurate answer
A quote request that includes every synthesis-relevant detail up front avoids the back-and-forth that eats into lead time. Providers price and schedule custom peptide production against exactly these variables, so vague requests get vague, padded quotes.
- State the exact sequence, written unambiguously with any non-standard residues flagged.
- Specify scale in milligrams or micromoles required.
- Set a purity target, expressed as a percentage by HPLC/UPLC.
- List all modifications: cyclisation, labelling, PEGylation or non-natural residues.
- Confirm terminal groups (free amine or acetylated N-terminus; free acid or amide C-terminus) and salt form.
- Specify physical format (lyophilised powder, in solution) and required documentation, including a COA.
Turnaround typically extends when a sequence is difficult to couple, when repurification is required to hit the purity target, or when a non-standard format is requested. Length, modification count and high-purity targets are the main cost drivers per residue in most commercial peptide synthesis services, with additional characterisation adding to both price and schedule.
Matching peptide specification to the assay
Over-specifying purity is one of the more common, avoidable costs in custom peptide orders. A >99% purity target makes sense for structural or highly quantitative work, but many cell-based or lower-sensitivity assays perform fine with peptide in the 70 to 95% range, and paying for headline purity you do not need only lengthens lead time.
What matters more than the number on the COA is the process behind it: ask providers directly about their re-synthesis and repurification policies, and how they monitor coupling efficiency batch to batch, rather than accepting a purity figure with no visibility into how consistently it is achieved.
— Dr. Authur
Reducing procurement risk with Australian-fulfilled peptides
There are alternative domestic providers for researchers seeking certainty on both purity and delivery.
That combination matters for procurement risk specifically: a documented COA means you are not relying on a supplier's word for identity and purity, and domestic dispatch means a delayed shipment doesn't stall a time-sensitive experiment. Discreet packaging is standard on every order. If you are ready to commission a custom peptide synthesis run, browse the current Metabolic & GLP-1 range or head to the Aupeptidelabs ordering page to submit your sequence, scale and purity requirements directly.
Sources
- Automated solid-phase peptide synthesis to obtain therapeutic peptides
- Guideline on the development and manufacture of synthetic peptides
FAQ
What is Fmoc-SPPS and why is it the standard method?
Fmoc solid-phase peptide synthesis builds a peptide chain on resin using base-labile protecting groups, which allows automated, orthogonal deprotection and coupling cycles. Its compatibility with standard building blocks and automated synthesisers makes it the practical default for research peptides, with Boc chemistry reserved for specialist cases.
How is peptide purity different from peptide identity?
Identity confirms the molecule has the correct mass through mass spectrometry (MALDI-TOF or ESI-MS), while purity measures what fraction of the sample is that correct sequence, determined by HPLC or UPLC integration. Both figures should appear on the COA supplied with a custom peptide order.
What information should I include in a custom peptide quote request?
Provide the exact sequence, scale in mg or µmol, purity target, any modifications, terminal groups, salt form, physical format and the analytical documentation you require. A complete request avoids delays and gets a more accurate lead-time and cost estimate.
Why does a difficult sequence take longer to synthesise?
Long, hydrophobic or heavily modified sequences are prone to incomplete coupling and on-resin aggregation, which reduces yield per cycle and often requires mitigation like pseudoproline building blocks or fragment condensation. Each mitigation step adds processing time on top of the standard synthesis cycle.
Does Aupeptidelabs provide a Certificate of Analysis with custom orders?
Current pricing and available research categories are listed on the Aupeptidelabs site.